Department of Nutrition and Food Science, Auburn University, AL 36849, USA.
Nutr Res Pract. 2008 Winter;2(4):200-3. doi: 10.4162/nrp.2008.2.4.200. Epub 2008 Dec 31.
Obesity has become a worldwide health problem. Orlistat, an inhibitor of pancreatic lipase, is currently approved as an anti-obesity drug. However, gastrointestinal side effects caused by Orlistat may limit its use. In this study the inhibitory activities of dandelion (Taraxacum officinale) against pancreatic lipase in vitro and in vivo were measured to determine its possible use as a natural anti-obesity agent. The inhibitory activities of the 95% ethanol extract of T. officinale and Orlistat were measured using 4-methylumbelliferyl oleate (4-MU oleate) as a substrate at concentrations of 250, 125, 100, 25, 12.5 and 4 microg/ml. To determine pancreatic lipase inhibitory activity in vivo, mice (n=16) were orally administered with corn oil emulsion (5 ml/kg) alone or with the 95% ethanol extract of T. officinale (400 mg/kg) following an overnight fast. Plasma triglyceride levels were measured at 0, 90, 180, and 240 min after treatment and incremental areas under the response curves (AUC) were calculated. The 95% ethanol extract of T. officinale and Orlistat, inhibited, porcine pancreatic lipase activity by 86.3% and 95.7% at a concentration of 250 microg/ml, respectively. T. officinale extract showed dose-dependent inhibition with the IC(50) of 78.2 microg/ml. A single oral dose of the extract significantly inhibited increases in plasma triglyceride levels at 90 and 180 min and reduced AUC of plasma triglyceride response curve (p<0.05). The results indicate that T. officinale exhibits inhibitory activities against pancreatic lipase in vitro and in vivo. Further studies to elucidate anti-obesity effects of chronic consumption of T. officinale and to identify the active components responsible for inhibitory activity against pancreatic lipase are necessary.
肥胖已成为全球性的健康问题。奥利司他是一种胰腺脂肪酶抑制剂,目前被批准为抗肥胖药物。然而,奥利司他引起的胃肠道副作用可能限制了其应用。本研究旨在测定蒲公英(Taraxacum officinale)在体外和体内对胰腺脂肪酶的抑制活性,以确定其作为天然抗肥胖剂的可能性。采用 4-甲基伞形酮油酸酯(4-MU 油酸酯)作为底物,在 250、125、100、25、12.5 和 4 μg/ml 浓度下测定蒲公英 95%乙醇提取物和奥利司他的抑制活性。为了确定蒲公英 95%乙醇提取物在体内的胰腺脂肪酶抑制活性,禁食过夜后,16 只小鼠(n=16)分别经口给予玉米油乳剂(5 ml/kg)或 95%乙醇提取物(400 mg/kg)。于给药后 0、90、180 和 240 min 时测定血浆三酰甘油水平,并计算反应曲线下面积(AUC)的增量。蒲公英 95%乙醇提取物和奥利司他在 250 μg/ml 浓度时分别抑制猪胰腺脂肪酶活性 86.3%和 95.7%。蒲公英 95%乙醇提取物呈浓度依赖性抑制,IC50 为 78.2 μg/ml。单次口服提取物可显著抑制血浆三酰甘油水平在 90 和 180 min 时的升高,并降低血浆三酰甘油反应曲线 AUC(p<0.05)。结果表明,蒲公英在体外和体内均具有抑制胰腺脂肪酶的活性。有必要进一步研究慢性摄入蒲公英对肥胖的抑制作用及其鉴定对胰腺脂肪酶抑制活性有贡献的活性成分。